Why Is SAB BIO Stock Trading Lower On Tuesday?
1. SAB BIO's SAB-142 met primary safety objectives for Phase 1 trial. 2. SAB-142 shows favorable safety profile and sustained immunomodulation. 3. Phase 2b trial for SAB-142 planned for 2025 in type 1 diabetes. 4. Current SABS stock price down 50.2% to $2.17 at last check.